As of Oct 18
| -0.29 / -0.19%|
The 26 analysts offering 12-month price forecasts for Vertex Pharmaceuticals Inc have a median target of 183.00, with a high estimate of 215.00 and a low estimate of 85.00. The median estimate represents a +18.25% increase from the last price of 154.76.
The current consensus among 28 polled investment analysts is to Buy stock in Vertex Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.